<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CYTOGAM- human cytomegalovirus immune globulin liquid </strong><br>CSL Behring AG<br></p></div>
<h1>Cytogam<span class="Sup">® </span><br>Cytomegalovirus Immune Globulin Intravenous (Human)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DL"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Liquid Formulation<br>Solvent Detergent Treated</span></p>
<p><span class="Bold">R<span class="Sub">x</span> only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Cytogam, Cytomegalovirus Immune Globulin Intravenous (Human) (CMV-IGIV), is an <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin G</span> (IgG) containing a standardized amount of antibody to Cytomegalovirus (CMV). CMV-IGIV is formulated in final vial as a sterile liquid. The globulin is stabilized with 5% sucrose and 1% Albumin (Human). Cytogam contains no preservative. The purified immunoglobulin is derived from pooled adult human plasma selected for high titers of antibody for Cytomegalovirus (CMV).<span class="Sup">1</span> Source material for fractionation may be obtained from another U.S. licensed manufacturer. Pooled plasma was fractionated by ethanol precipitation of the proteins according to Cohn Methods 6 and 9, modified to yield a product suitable for intravenous administration. A widely utilized solvent-detergent viral inactivation process is also used.<span class="Sup">2</span> Certain manufacturing operations may be performed by other firms. Each milliliter contains: 50 ± 10 mg of immunoglobulin, primarily IgG, and trace amounts of IgA and IgM; 50 mg of sucrose; 10 mg of Albumin (Human). The sodium content is 20-30 mEq per liter, i.e., 0.4-0.6 mEq per 20 mL or 1.0-1.5 mEq per 50 mL. The solution should appear colorless and translucent.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Cytogam contains IgG antibodies representative of the large number of normal persons who contributed to the plasma pools from which the product was derived. The globulin contains a relatively high concentration of antibodies directed against Cytomegalovirus (CMV). In the case of persons who may be exposed to CMV, Cytogam can raise the relevant antibodies to levels sufficient to attenuate or reduce the incidence of serious CMV disease.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Cytomegalovirus Immune Globulin Intravenous (Human) is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart. In transplants of these organs other than kidney from CMV seropositive donors into seronegative recipients, <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> CMV-IGIV should be considered in combination with ganciclovir.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-5"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">Clinical studies have shown a 50% reduction in primary CMV disease in renal transplant patients given CMV-IGIV<span class="Sup">3</span> and a 56% reduction in serious CMV disease<span class="Sup">4</span> in liver transplant patients given CMV-IGIV. CMV-IGIV prophylaxis was associated with increased survival in liver transplant recipients.<span class="Sup">5</span></p>
<p>In two separate clinical trials, Cytogam was shown to provide effective prophylaxis in renal transplant recipients at risk for primary CMV disease. In the first randomized trial,<span class="Sup">3</span> the incidence of virologically confirmed CMV-associated syndromes was reduced from 60% in controls (n=35) to 21% in recipients of CMV immune globulin (n=24) (P &lt; 0.01); marked <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> was reduced from 37% in controls to 4% in globulin recipients (P &lt; 0.01); and fungal or parasitic <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> were not seen in globulin recipients but occurred in 20% of controls (P = 0.05). Serious CMV disease was reduced from 46% to 13%. There was a concomitant but not statistically significant reduction in the incidence of CMV <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (17% of controls as compared with 4% of globulin recipients). There was no effect on rates of viral isolation or seroconversion although the rate of <span class="product-label-link" type="condition" conceptid="133327" conceptname="Viremia">viremia</span> was less in Cytogam recipients. In a subsequent non-randomized trial in renal transplant recipients (n=36),<span class="Sup">6</span> the incidence of virologically confirmed CMV-associated syndrome was reduced to 36% in the globulin recipients in comparison to a 60% incidence in control patients (n=35) in the randomized trial. The rates of serious CMV disease, and concomitant fungal and parasitic <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> were similar to patients receiving CMV-IGIV in the first trial.</p>
<p>In a randomized, double-blind, placebo-controlled trial in liver transplant recipients,<span class="Sup">4</span> the incidence of serious CMV-associated disease was reduced from 26% in the 72 control patients to 12% in the 69 CMV-IGIV recipients (p=0.02); serious CMV-associated disease included CMV disease in 2 or more organs, CMV <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, or CMV-associated invasive <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, the incidence of which was 18% in controls and 7% in CMV-IGIV recipients (p=0.04). In follow-up<span class="Sup">5</span> of the liver transplant patients studied in this randomized controlled trial and a subsequent open-label trial,<span class="Sup">7</span> the one year survival of the 72 control patients was 72% versus 86% in the 90 recipients of CMV-IGIV (p=0.03). In the randomized control trial, the reduction in serious CMV-associated disease in CMV seronegative recipients of livers from a CMV seropositive donor (7/19 in the CMV-IGIV group vs. 9/19 in control) was less than in transplants with other donor and recipient serologic status (1/50 in the CMV-IGIV group vs. 10/53 in the control group). This finding was similar to that of Merigan et al.<span class="Sup">8</span> in a study of ganciclovir prophylaxis after heart transplantation. In this study, patients received ganciclovir IV at 5 mg/kg twice a day for the initial 14 days post-transplant, then at 6 mg/kg each day for 5 days per week through day 28. </p>
<p>Recent studies of combined prophylaxis with CMV-IGIV and ganciclovir have shown reductions in the incidence of serious CMV associated disease in CMV seronegative recipients of CMV seropositive organs below that expected from one drug alone.<span class="Sup">9-12</span></p>
<p>Ham et al.<span class="Sup">9</span> used CMV-IGIV with a dosage schedule of 150 mg/kg CMV-IGIV within 72 hours of transplant; 100 mg/kg at two, four, six and eight weeks following liver transplant and then 50 mg/kg at 12 and 16 weeks post-transplant in combination with ganciclovir (10 mg/kg/day for 14 days). The incidence of CMV disease was reduced from an expected 60-80% rate to 7% in 15 seronegative recipients of a seropositive organ.</p>
<p>Snydman<span class="Sup">10</span> using the CMV-IGIV dosage schedule listed under <span class="Italics"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span> section in combination with ganciclovir (10 mg/kg/day for 14 days) reduced the incidence of serious CMV disease in D+R- liver transplant recipients receiving placebo or one drug from 16/47 (34%) to 3/41 (7%) in patients receiving both drugs for prophylaxis. </p>
<p>Martin<span class="Sup">11</span> using CMV-IGIV 100 mg/kg every two weeks for six weeks followed by 50 mg/kg every two weeks with a final dose at week 16, in combination with ganciclovir 10 mg/kg/day for 14 days after transplantation, observed severe CMV disease in 1/74 (1%) of CMV seronegative recipients of a kidney from a CMV seropositive donor, in 0/14 (0%) of CMV seronegative recipients of a kidney-pancreas transplant from a CMV seropositive donor and in 1/12 (8%) of CMV seronegative recipients of a liver from a CMV seropositive donor. The incidence of serious CMV disease with combined CMV-IGIV and ganciclovir prophylaxis was lower than previous experience with single drug prophylaxis.</p>
<p>Valantine and Luikart<span class="Sup">12</span> compared prophylaxis with CMV-IGIV (biweekly for three months) in combination with ganciclovir prophylaxis (IV at 5 mg/kg twice a day for the initial 14 days post-transplant, then at 6 mg/kg through day 28) in 16 CMV seronegative recipients of hearts from CMV seropositive donors with 16 matched controls receiving ganciclovir alone. The actuarial incidence of CMV disease was reduced from 55% in the ganciclovir group to 46% in the combined group (p≤ 0.06) and survival was increased from 61% to 94% (p≤ 0.001). In heart-lung or lung transplant patients in whom either the donor or recipient was CMV seropositive, the actuarial incidence of CMV disease in patients receiving ganciclovir alone (n=25) was 85% as compared to 36% of the 33 patients receiving both CMV-IGIV and ganciclovir (p≤ 0.05). Survival was 60% in the ganciclovir group and 80% in patients receiving CMV-IGIV and ganciclovir (p≤ 0.01).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Cytogam should not be used in individuals with a history of a prior severe reaction associated with the administration of this or other human immunoglobulin preparations. Persons with selective immunoglobulin A deficiency have the potential for developing antibodies to immunoglobulin A and could have <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to subsequent administration of blood products that contain immunoglobulin A, including Cytogam.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">CMV-IGIV is made from human plasma and, like other plasma products, carries the possibility for transmission of blood-borne viral agents and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk of transmission of recognized blood-borne viruses is considered to be low because of the viral inactivation and removal properties in the Cohn-Oncley <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> ethanol precipitation procedure used for purification of immune globulin products.<span class="Sup">13-15</span> Until 1993, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> ethanol manufactured immune globulins licensed in the United States had not been documented to transmit any viral agent. However, during a brief period in late 1993 to early 1994, intravenous immune globulin made by one U.S. manufacturer was associated with transmission of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C virus.<span class="Sup">16</span> To further guard against possible transmission of blood-borne viruses, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C, CMV-IGIV is treated with a solvent detergent viral inactivation procedure<span class="Sup">2</span> known to inactivate a wide spectrum of lipid enveloped viruses, including HIV-1, HIV-2, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B, and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C.<span class="Sup">17</span> However, because new blood-borne viruses may yet emerge, some of which may not be inactivated by the manufacturing process or by solvent detergent treatment, CMV-IGIV, like any other blood product, should be given only if a benefit is expected.</p>
<p>Immune Globulin Intravenous (Human) products have been reported to be associated with renal dysfunction, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, osmotic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.<span class="Sup">18-25</span> Patients predisposed to <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> include patients with any degree of pre-existing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, age greater than 65, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="441532" conceptname="Monoclonal paraproteinemia">paraproteinemia</span> or patients receiving known nephrotoxic drugs. Especially in such patients, IGIV products should be administered at the minimum concentrations available and the minimum rate of infusion practicable. While these reports of renal dysfunction and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> have been associated with the use of many IGIV products, those containing sucrose as a stabilizer (and given at daily doses of 350 mg/kg or greater) account for a disproportionate share of the total number.<span class="Sup">18</span> Cytogam contains sucrose as a stabilizer. See <span class="Italics"><a href="#Precautions">PRECAUTIONS</a></span> and <span class="Italics"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span> sections for important information intended to reduce the risk of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.</p>
<p>During administration, the patient's vital signs should be monitored continuously and careful observation made for any symptoms throughout the infusion. Epinephrine should be available for the treatment of an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">acute anaphylactic reaction</span> (<span class="Italics">see <a href="#Precautions">PRECAUTIONS</a></span> section).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Precautions"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">Cytogam does not contain a preservative. The vial should be entered only once for administration purposes and the infusion should begin within 6 hours. The infusion schedule should be adhered to closely (see <span class="Italics"><a href="#Infusion">Infusion</a></span> section). Do not use if the solution is turbid.</p>
<p>Although <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reactions</span> are rare (see <span class="Italics"><a href="#AR">ADVERSE REACTIONS</a></span> section), epinephrine and diphenhydramine should be available for treatment of acute allergic symptoms. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> occur, the administration of the immunoglobulin should be discontinued immediately and an antidote should be given as noted above.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Renal Function</h2>
<p class="First">Assure that patients are not volume depleted prior to the initiation of IGIV. Periodic monitoring of renal function tests and urine output is particularly important in patients judged to have a potential increased risk for developing <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. Renal function, including the measurement of blood urea nitrogen (BUN) and serum creatinine should be assessed prior to the initial infusion of Cytogam and again at appropriate intervals thereafter. If renal function deteriorates, discontinuation of the product should be considered. The recommended rate of Cytogam infusion for prophylaxis of CMV disease in solid organ transplant patients is 60 mg Ig/kg/hr (<span class="Italics">see <a href="#DA">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span> Syndrome</h2>
<p class="First">An <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span> syndrome (AMS) has been reported to occur infrequently in association with Immune Globulin Intravenous (Human) (IGIV) treatment.<span class="Sup">26-29</span> The syndrome usually begins within several hours to two days following IGIV treatment. It is characterized by symptoms and signs including severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">nuchal rigidity</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, painful eye movements, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Cerebrospinal fluid (CSF) studies are frequently positive with <span class="product-label-link" type="condition" conceptid="4240184" conceptname="Pleocytosis">pleocytosis</span> up to several thousand cells per cu.mm., predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dL. Patients exhibiting such symptoms and signs should receive a thorough neurological examination, including CSF studies, to rule out other causes of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. AMS may occur more frequently in association with high dose (2 g/kg) IGIV treatment. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span></h2>
<p class="First">Immune Globulin Intravenous (Human) (IGIV) products can contain blood group antibodies which may act as hemolysins and induce <span class="Italics">in vivo</span> coating of red blood cells with immunoglobulin, causing a positive direct antiglobulin reaction and, rarely, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>.<span class="Sup">30-32</span> <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span> can develop subsequent to IGIV therapy due to enhanced RBC sequestration<span class="Sup">33</span> [<span class="Italics">see <a href="#AR">ADVERSE REACTIONS</a></span>]. IGIV recipients should be monitored for clinical signs and symptoms of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> [<span class="Italics">see <a href="#PreLT">PRECAUTIONS: Laboratory Tests</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2>Transfusion-Related Acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>)</h2>
<p class="First">There have been reports of noncardiogenic <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> [Transfusion-Related Acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>)] in patients administered IGIV.<span class="Sup">34</span> <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> is characterized by severe <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, normal left ventricular function, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and typically occurs within 1-6 hours after transfusion. Patients with <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> may be managed using oxygen therapy with adequate ventilatory support.</p>
<p>IGIV recipients should be monitored for pulmonary adverse reactions. If <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> is suspected, appropriate tests should be performed for the presence of anti-neutrophil antibodies in both the product and patient serum [<span class="Italics">see <a href="#PreLT">PRECAUTIONS: Laboratory Tests</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2>Thrombotic Events</h2>
<p class="First">Thrombotic events have been reported in association with IGIV<span class="Sup">35-37</span> (<span class="Italics">see <a href="#AR">ADVERSE REACTIONS</a></span>). Patients at risk may include those with a history of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>, multiple cardiovascular risk factors, advanced age, impaired <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, and/or known or suspected hyperviscosity. The potential risks and benefits of IGIV should be weighed against those of alternative therapies for all patients for whom IGIV administration is being considered. Baseline assessment of blood viscosity should be considered in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies [<span class="Italics">see <a href="#PreLT">PRECAUTIONS: Laboratory Tests</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="PreLT"></a><a name="section-8.7"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">If signs and/or symptoms of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> are present after IGIV infusion, appropriate confirmatory laboratory testing should be done [<span class="Italics">see <a href="#PreLT">PRECAUTIONS</a></span>].</p>
<p>If <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> is suspected, appropriate tests should be performed for the presence of anti-neutrophil antibodies in both the product and the patient serum [<span class="Italics">see <a href="#Precautions">PRECAUTIONS</a></span>].</p>
<p>Because of the potentially increased risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, baseline assessment of blood viscosity should be considered in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies [<span class="Italics">see <a href="#Precautions">PRECAUTIONS</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8.8"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Antibodies present in immune globulin preparations may interfere with the immune response to live virus vaccines such as <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>, and <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span>; therefore, vaccination with live virus vaccines should be deferred until approximately three months after administration of Cytogam. If such vaccinations were given shortly after Cytogam, a revaccination may be necessary. Admixtures of Cytogam with other drugs have not been evaluated. It is recommended that Cytogam be administered separately from other drugs or medications which the patient may be receiving (<span class="Italics">see <a href="#DA">DOSAGE AND ADMINISTRATION</a></span> section).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.9"></a><p></p>
<h2>Pregnancy Category C</h2>
<p class="First">Animal reproduction studies have not been conducted with Cytomegalovirus Immune Globulin Intravenous (Human). It is also not known whether Cytomegalovirus Immune Globulin Intravenous (Human) can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cytomegalovirus Immune Globulin Intravenous (Human) should be given to a pregnant woman only if clearly needed. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8.10"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be instructed to report all <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> directly to their physician and to CSL Behring Pharmacovigilance at 1-866-915-6958. The risks and benefits of this product should be discussed with the patient. In addition, patients should be instructed to immediately report symptoms of decreased urine output, sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, and/or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> (which may suggest kidney damage) to their physician.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Minor reactions such as <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> were the most frequent adverse reactions observed during the clinical trials of Cytogam, Cytomegalovirus Immune Globulin Intravenous (Human). The incidence of these reactions during the clinical trials was less than 6.0% of all infusions and such reactions were most often related to infusion rates. A decrease in blood pressure was observed in 1 of 1039 infusions in clinical trials of Cytogam. If a patient develops a minor side effect, <span class="Italics">slow the rate</span> immediately or temporarily interrupt the infusion.</p>
<p>Increases in serum creatinine and blood urea nitrogen (BUN) have been observed as soon as one to two days following IGIV infusion. Progression to <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> requiring dialysis has been observed. Types of severe renal adverse events that have been seen following IGIV therapy include <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">acute tubular necrosis</span>, proximal tubular <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> and osmotic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>.<span class="Sup">18-25</span></p>
<p>Severe reactions such as <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, although not observed during clinical trials, are a possibility. Clinical <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> may occur even when the patient is not known to be sensitized to immune globulin products. A reaction may be related to the rate of infusion; therefore, carefully adhere to the infusion rates as outlined under "<span class="Italics"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span>."  If <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span> occurs, <span class="Italics">discontinue infusion</span> and use antidote such as diphenhydramine and adrenalin.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Postmarketing</h2>
<p class="First">The following adverse reactions have been identified and reported during the post-approval use of IGIV products:<span class="Sup">38</span></p>
<p><span class="Bold Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span>, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Acute Respiratory Distress Syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>), Transfusion-Related Acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>), <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span><br><span class="Bold Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">vascular collapse</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span><br><span class="Bold Italics">Neurological:</span> <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span><br><span class="Bold Italics">Integumentary:</span> <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4309632" conceptname="Epidermolysis">epidermolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">bullous dermatitis</span><br><span class="Bold Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, positive direct antiglobulin (Coombs) test<br><span class="Bold Italics">General/Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span><br><span class="Bold Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span><br><span class="Bold Italics">Gastrointestinal</span><span class="Italics">:</span> Hepatic dysfunction, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p>
<p>Because postmarketing reporting of these reactions is voluntary and the at-risk populations are of uncertain size, it is not always possible to reliably estimate the frequency of the reaction or establish a causal relationship to exposure to the product. Such is also the case with literature reports authored independently.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Although few data are available, clinical experience with other immunoglobulin preparations suggests that the major manifestations would be those related to volume overload.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The maximum recommended total dosage per infusion is 150 mg Ig/kg, administered according to the following schedule: </p>
<table width="80%">
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="2"><span class="Underline">Type of Transplant</span></th>
</tr>
<tr class="Last">
<th align="left"></th>
<th align="center">Kidney</th>
<th align="center">Liver, Pancreas, Lung, Heart</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left">Within 72 hours of transplant: </td>
<td align="center">150 mg/kg</td>
<td align="center">150 mg/kg</td>
</tr>
<tr>
<td align="left">            2 weeks post transplant: </td>
<td align="center">100 mg/kg</td>
<td align="center">150 mg/kg</td>
</tr>
<tr>
<td align="left">            4 weeks post transplant: </td>
<td align="center">100 mg/kg</td>
<td align="center">150 mg/kg</td>
</tr>
<tr>
<td align="left">            6 weeks post transplant: </td>
<td align="center">100 mg/kg</td>
<td align="center">150 mg/kg</td>
</tr>
<tr>
<td align="left">            8 weeks post transplant: </td>
<td align="center">100 mg/kg</td>
<td align="center">150 mg/kg</td>
</tr>
<tr>
<td align="left">           12 weeks post transplant: </td>
<td align="center">50 mg/kg</td>
<td align="center">100 mg/kg</td>
</tr>
<tr class="Last">
<td align="left">           16 weeks post transplant: </td>
<td align="center">50 mg/kg</td>
<td align="center">100 mg/kg</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2>Preparation for Administration</h2>
<p class="First">Remove the tab portion of the vial cap and clean the rubber stopper with 70% alcohol or equivalent. DO NOT SHAKE VIAL; AVOID FOAMING.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Infuse the solution only if it is colorless, free of particulate matter and not turbid.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Infusion"></a><a name="section-11.2"></a><p></p>
<h2>Infusion</h2>
<p class="First">Infusion should begin within 6 hours after entering the vial and should be complete within 12 hours of entering the vial. Vital signs should be taken preinfusion, mid-way and post-infusion as well as before any rate increase. Cytogam should be administered through an intravenous line using an administration set that contains an in-line filter (pore size 15µ) and a constant infusion pump (i.e., IVAC pump or equivalent). A smaller in-line filter (0.2µ) is also acceptable. Pre-dilution of Cytogam before infusion is not recommended. Cytogam should be administered through a separate intravenous line. If this is not possible, Cytogam may be "piggybacked" into a pre-existing line if that line contains either Sodium Chloride Injection, USP, or one of the following dextrose solutions (with or without NaCl added): 2.5% dextrose in water, 5% dextrose in water, 10% dextrose in water, 20% dextrose in water. If a pre-existing line must be used, the Cytogam should not be diluted more than 1:2 with any of the above-named solutions. Admixtures of Cytogam with any other solutions have not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3"></a><p></p>
<h2>Initial Dose</h2>
<p class="First">Administer intravenously at 15 mg Ig per kg body weight per hour. If no adverse reactions occur after 30 minutes, the rate may be increased to 30 mg Ig/kg/hr; if no adverse reactions occur after a subsequent 30 minutes, then the infusion may be increased to 60 mg Ig/kg/hr (volume not to exceed 75 mL/hour). DO NOT EXCEED THIS RATE OF ADMINISTRATION. The patient should be monitored closely during and after each rate change. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4"></a><p></p>
<h2>Subsequent Doses</h2>
<p class="First">Administer at 15 mg Ig/kg/hr for 15 minutes. If no adverse reactions occur, increase to 30 mg Ig/kg/hr for 15 minutes and then increase to a maximum rate of 60 mg Ig/kg/hr (volume not to exceed 75 mL/hour). DO NOT EXCEED THIS RATE OF ADMINISTRATION. The patient should be monitored closely during each rate change. </p>
<p>Cytogam should be used with caution in patients with pre-existing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and in patients judged to be at increased risk of developing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (including, but not limited to those with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, age greater than 65, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, <span class="product-label-link" type="condition" conceptid="441532" conceptname="Monoclonal paraproteinemia">paraproteinemia</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> and patients receiving known nephrotoxic drugs). In these cases especially, it is important to assure that patients are not volume depleted prior to Cytogam infusion. While most cases of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> have occurred in patients receiving total doses of 350 mg Ig/kg or greater, no prospective data are presently available to identify a maximum safe dose, concentration or rate of infusion in patients determined to be at increased risk of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. In the absence of prospective data, recommended doses should not be exceeded and the concentration and infusion rate selected should be the minimum practicable.</p>
<p>Potential adverse reactions are: <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span>. Minor adverse reactions have been infusion rate related – if the patient develops a minor side effect (i.e., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>), slow the rate or temporarily interrupt the infusion. If <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span> occurs, discontinue infusion and use antidote such as diphenhydramine and adrenalin.</p>
<p>To prevent the transmission of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> viruses or other infectious agents from one person to another, sterile disposable syringes and needles should be used. The syringes and needles should not be reused.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Cytogam is supplied in a 50 mL single-dose vial (50 mg/mL).</p>
<p>The product presentation includes a package insert and the following component:</p>
<table width="100%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="left" valign="top" width="60%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Presentation</th>
<th class="Rrule" align="center">Carton<br>NDC Number</th>
<th class="Rrule" align="left">Component</th>
</tr></thead>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="center">2.5 g</td>
<td class="Rrule" align="center">44206-532-11</td>
<td class="Rrule" align="left">Cytogam in a single-use vial [NDC 44206-532-90]</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<h2>STORAGE</h2>
<p class="First">Cytogam should be stored between 2-8°C (36-46°F), and used within 6 hours after entering the vial.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Snydman DR, McIver J, Leszczynski J, et al. A pilot trial of a novel cytomegalovirus immune globulin in renal transplant recipients. Transplantation 1984;38:553-557.</li>
<li>Horowitz B, Wiebe ME, Lippin A, et al. Inactivation of viruses in labile blood derivatives. Transfusion 1985;25:516-522.</li>
<li>Snydman DR, Werner BG, Heinze-Lacey BH, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. N Engl J Med 1987;317:1049-1054.</li>
<li>Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus Immune Globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Int Med 1993;119:984-991.</li>
<li>Falagas ME, Snydman DR, Ruthazer R, et al. Cytomegalovirus Immune Globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. Clin Transplant 1997;11:432-437.</li>
<li>Snydman DR, Werner BG, Tilney NL, et al. A final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: Comparison of randomized and open-label trials. Transplant Proc 1991;23:1357-1360.</li>
<li>Snydman DR, Werner BG, Dougherty NN, et al. A further analysis of the use of Cytomegalovirus Immune Globulin in orthotopic liver transplant patients at risk for primary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Transplant Proc 1994;26 Suppl 1:23-27.</li>
<li>Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992;326:1182-1186.</li>
<li>Ham JM, Shelden SR, Godkin RR, et al. Cytomegalovirus prophylaxis with ganciclovir, acyclovir and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction. Transplant Proc 1995;27 (5 Suppl 1):31-33.</li>
<li>Snydman DR. Combined CMV-IGIV and ganciclovir prophylaxis in CMV seronegative transplant recipients from CMV seropositive donors. Report on file.</li>
<li>Martin M. CMV prophylaxis with combination ganciclovir and CMV hyperimmune globulin followed by high-dose acyclovir in solid organ transplant recipients. Report on file.</li>
<li>Valantine H, Luikart H. Impact of CMV hyperimmune globulin on outcome after cardiothoracic transplantation: A comparative study of combined prophylaxis with CMVIG plus ganciclovir vs. ganciclovir alone. Report on file.</li>
<li>Bossell, et al. Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III / <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>-associated virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. MMWR 1996;35:231-233.</li>
<li>Wells MA, Wittek AE, Epstein JS, et al. Inactivation and partition of human T-cell lymphotropic virus type III, during ethanol fractionation of plasma. Transfusion 1986;26:210-213.</li>
<li>McIver J, Grady G. Immunoglobulin preparations. In: Churchill WH, and Kurtz SR, editors. Transfusion Medicine. Boston: Blackwell Scientific Publications; 1988.</li>
<li>Schneider L, Geha R. Outbreak of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C associated with intravenous immunoglobulin administration – United States, October 1993 - June 1994. MMWR 1994;43:505-509.</li>
<li>Edwards CA, Piet MPJ, Chin S, et al. Tri(nButyl) phosphate detergent treatment of licensed therapeutic and experimental blood derivatives. Vox Sang 1987;52:53-59.</li>
<li>Cayco AV, Perazella MA, Hayslett JP. <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal insufficiency</span> after intravenous immune globulin therapy: A report of two cases and an analysis of the literature. J Am Soc Nephrol 1997;8:1788-1794.</li>
<li>Cantu TG, Hoehn-Saric EW, Burgess KM, Racusen L, Scheel PJ. <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> associated with immunoglobulin therapy. Am J Kidney Dis 1995;25:228-234.</li>
<li>Hansen-Schmidt S, Silomon J, Keller F. Osmotic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span> due to high-dose intravenous immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>. Am J Kidney Dis 1996;28: 451-453.</li>
<li>Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR. <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> resulting from intravenous immunoglobulin therapy. Arch Neurol 1993;50:137-139.</li>
<li>Winward D, Brophy MT. <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> after administration of intravenous immunoglobulin: Review of the literature and case report. Pharmacotherapy 1995;15:765-772.</li>
<li>Phillips AO. <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span> and intravenous immunoglobulin [letter; comment]. Clin Nephrol 1992;37:217.</li>
<li>Lindberg HA, Wald MH, Barker MH. Renal changes following administration of hypertonic solutions. Arch Intern Med 1939;63:907-918.</li>
<li>Rigdon RH, Cardwell ES. Renal lesions following the intravenous injection of a hypertonic solution of sucrose. Arch Intern Med 1942;69:670-690.</li>
<li>Sekul E, Culper E, Dalakas M. <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span> associated with high-dose intravenous immunoglobulin therapy; Frequency and risk factors. Ann Intern Med 1994;121:259-262.</li>
<li>Kato E, Shindo S, Eto Y, et al. Administration of immune globulin associated with <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>. JAMA 1988; 259:3269-3270.</li>
<li>Casteels Van Daele M, Wijindaele L, Hunnick K, et al. Intravenous immunoglobulin and acute <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>. N Engl J Med 1990;323:614-615.</li>
<li>Scribner C, Kapit R, Philips E, et al. <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span> and intravenous immunoglobulin therapy. Ann Intern Med 1994;121:305-306.</li>
<li>Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ. <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span> following intravenous immune globulin therapy. Transfusion 1986;26:410-412.</li>
<li>Thomas MJ, Misbah SA, Chapel HM, Jones M, Elrington G, Newsom-Davis J. <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span> after high-dose intravenous Ig. Blood 1993;15:3789.</li>
<li>Reinhart WH, Berchtold PE. Effect of high dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992;339:662-664.</li>
<li>Kessary-Shoham H, Levy Y, Shoenfeld Y, Lorber M, Gershon H. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J Autoimmun 1999;13:129-135.</li>
<li>Rizk A, Gorson KC, Kenney L, Weinstein R. Transfusion-related acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">lung injury</span> after the infusion of IVIG. Transfusion 2001;41:264-268.</li>
<li>Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitant <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>. Neurology 1994;44:223-226.</li>
<li>Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of <span class="product-label-link" type="condition" conceptid="4028065" conceptname="Autoimmune thrombocytopenia">autoimmune thrombocytopenia</span> with intravenous immunoglobulin in elderly patients. Lancet 1986;2:217-218.</li>
<li>Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000;65:30-34.</li>
<li>Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Trans Med Rev 2003;17:241-251.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">For additional information concerning Cytomegalovirus Immune Globulin Intravenous (Human) contact:<br>CSL Behring Medical Affairs<br>CSL Behring LLC<br>King of Prussia, PA 19406 USA<br>1-800-504-5434</p>
<p>Manufactured by:<br><span class="Bold">CSL Behring AG</span><br>Bern, Switzerland<br>US License No. 1766</p>
<p>Distributed by:<br><span class="Bold">CSL Behring LLC</span><br>Kankakee, IL 60901 USA</p>
<p>Revised August 2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 50 mL Vial Label</h1>
<p class="First"><span class="Bold">Cytomegalovirus<br>Immune Globulin Intravenous (Human)<br>Cytogam<span class="Sup">®</span></span></p>
<p><span class="Bold">NDC 44206-532-90</span></p>
<p>2500 mg IgG Liquid</p>
<p><span class="Bold">Liquid Formulation Solvent Detergent Treated</span><br>Store between 2–8°C (36–46°F). <span class="Bold">DO NOT SHAKE VIAL; AVOID FOAMING.</span><br>FOR INTRAVENOUS ADMINISTRATION ONLY. See package insert for dosage<br>and administration. Begin administration within 6 hours after container has<br>been entered. Contains no preservative. A widely used solvent detergent viral<br>inactivation process is used in the preparation of this product.</p>
<p><span class="Bold">Rx only</span></p>
<p>A8303/129</p>
<p>Manufactured by:<br><span class="Bold">CSL Behring AG</span><br>Bern, Switzerland<br>US License No. 1766</p>
<p>Distributed by:<br><span class="Bold">CSL Behring LLC</span><br>Kankakee, IL 60901<br>USA</p>
<p><span class="Bold">2.5 g</span></p>
<p class="Bold">50 mL</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 50 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d72d56e3-1f27-4ec1-a49d-7c0f8f5bc512&amp;name=cytogam-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 50 mL Vial Carton</h1>
<p class="First"><span class="Bold">NDC 44206-532-11</span></p>
<p><span class="Bold">2.5 g</span></p>
<p><span class="Bold">50 mL</span></p>
<p><span class="Bold">Cytomegalovirus<br>Immune Globulin<br>Intravenous<br>(Human)<br>Cytogam<span class="Sup">®</span></span></p>
<p><span class="Bold">Liquid Formulation<br>Solvent Detergent Treated</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">2500</span> mg IgG, <span class="Bold">2500</span> mg Sucrose<br><span class="Bold">500</span> mg Albumin (Human)<br>Liquid</p>
<p><span class="Bold">CSL Behring</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 50 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d72d56e3-1f27-4ec1-a49d-7c0f8f5bc512&amp;name=cytogam-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CYTOGAM 		
					</strong><br><span class="contentTableReg">human cytomegalovirus immune globulin liquid</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:44206-532</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Human Cytomegalovirus Immune Globulin</strong> (Human Cytomegalovirus Immune Globulin) </td>
<td class="formItem">Human Cytomegalovirus Immune Globulin</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Human Immunoglobulin A</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Human Immunoglobulin M</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Albumin (Human)</strong></td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sucrose</strong></td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:44206-532-11</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:44206-532-90</td>
<td class="formItem">50 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103189</td>
<td class="formItem">01/06/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>CSL Behring AG
							(481152762)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">CSL Behring AG</td>
<td class="formItem"></td>
<td class="formItem">481152762</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>956999c6-95ee-4889-b149-4ab73f43f931</div>
<div>Set id: d72d56e3-1f27-4ec1-a49d-7c0f8f5bc512</div>
<div>Version: 2</div>
<div>Effective Time: 20120822</div>
</div>
</div> <div class="DistributorName">CSL Behring AG</div></p>
</body></html>
